key: cord-0887986-9e1gcbrf authors: Doyle, Eileen B.; Bentley, Darren; Dodds, Michael G. title: COVID‐19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab date: 2021-09-14 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.15009 sha: d58b7011de90a0cb5ecd7ed79a8eb0d67eac1859 doc_id: 887986 cord_uid: 9e1gcbrf AIMS: To assess the potential of interleukin‐6 (IL‐6) signalling blockade in the lung to treat SARS‐CoV‐2 infection via model‐based simulation by exploring soluble IL‐6 receptor (sIL‐6R) sequestration by tocilizumab (TCZ) and IL‐6 sequestration by siltuximab (SIL). METHODS: Literature values of IL‐6, IL‐6 antagonist SIL, sIL‐6R, IL‐6R antagonist TCZ and their respective binding constants were used to develop a model to predict the impact of treatment on IL‐6 signalling. Models were used to generate simulated bronchoalveolar lavage fluid concentrations for normal subjects, subjects at risk of developing acute respiratory distress syndrome (ARDS), and subjects with ARDS under 4 conditions: without treatment; treatment with TCZ; treatment with SIL; and treatment with TCZ + SIL. RESULTS: With TCZ intervention, IL‐6 levels are unaffected and sIL‐6R is reduced somewhat below the Normal case. IL‐6:sIL‐6R complex only slightly decreased relative to the no‐intervention case. With SIL intervention, sIL‐6R levels are unaffected and IL‐6 is greatly reduced below the Normal case. IL‐6:sIL‐6R complex is greatly decreased relative to the no‐intervention case. With TCZ + SIL intervention, IL‐6 and sIL‐6R levels are reduced below the Normal case and achieve suppression equivalent to monotherapy results for their respective targets. IL‐6:sIL‐6R complex reduction is predicted to be greater than that achieved with monotherapy. This reflects sequestration of both components of the complex and the nonlinear binding equilibrium. CONCLUSION: Coadministration of both IL‐6 and IL‐6R sequestering products such as SIL and TCZ may be necessary to effectively treat COVID‐19 patients who have or are at risk of developing ARDS. Interleukin-6 (IL-6) plays multiple roles in the immune response, and seems to play a major role in COVID-19 ARDS. A metaanalysis of studies investigating the immunological response of COVID-19 revealed mean IL-6 concentrations were 2.9-fold higher in patients with complicated COVID-19 compared with patients with noncomplicated disease. 3 Results of single-centre studies continue to support this finding. Mortality rates among patients with elevated IL-6 of up to 5% have been reported, with corresponding mortality rates in patients with normal serum IL-6 of the order of 0.16%. 4 Results from deep-profiling longitudinal studies using whole-blood proteomics identified 23 clusters of cytokines that are differentially expressed in patients with mild disease, severe disease without end organ damage and severe disease with end organ damage. Patients with severe disease had increased IL-6 and other proinflammatory cytokines, with typical IL-6 levels of 30-400 pg-mL-1, consistent with non-COVID-19 ARDS elevation of IL- 6. 5 No studies in COVID-19 ARDS have quantified IL-6's cognate receptors soluble IL-6R (sIL-6R), membrane-bound IL-6R (mIL-6R), or other proteins necessary for IL-6 signalling (glycoprotein 130 [gp130] or soluble gp130 [sgp130]). IL-6 pathway blockade has been discussed, with focus on IL-6 inhibitors, which include the IL-6R antagonists such as sarilumab and tocilizumab (TCZ) as well as the IL-6 antagonist siltuximab (SIL). This study references a clinical example from non-COVID- 19 ARDS, in which the concentrations of serum IL-6, sIL-6R and the IL-6: sIL-6R complex were measured in bronchoalveolar lavage fluid (BALF) of patients with or at risk for non-COVID-19 ARDS, in order to develop a model for COVID-19 ARDS. In classic IL-6 signalling, IL-6 binds membrane-bound IL-6R (mIL-6R), then the complex binds with and dimerizes the glycoprotein 130 (gp130) transmembrane protein to elicit signal transduction. 6 mIL-6R is only found on certain cell types (such as macrophages, neutrophils, some T cells, and all hepatocytes). The classic signalling pathway has been associated with anti-inflammatory, or protective, effects of IL-6 signalling. 6 What is already known about this subject Most of these patients will require intensive care and respiratory support. Respiratory deterioration is concomitant with high levels of inflammatory markers, including but not limited to interleukin-6 (IL-6) and IL-6receptor (IL-6R). • Treatment with IL-6 inhibitors (such as siltuximab) and IL- • The combination of IL-6 inhibitors and IL-6R inhibitors has not been studied in clinical trials. Results from this simulation study of the combination of tocilizumab and siltuximab suggest that the combination may provide more efficient clearance of IL-6 and, consequently, enhance the effect of IL-6R blockade, as compared to the use of individual agents. • This study is an example of the use of modelling and simulation to aid in consideration of drugs to repurpose for the treatment of SARS-CoV-2. Trans signalling relies on soluble IL-6R (sIL-6R), which is constitutively present in all tissue types at ng mL-1 concentrations. 6 IL-6 binds sIL-6R, then the IL-6:sIL-6R complex binds and dimerizes gp130, leading to signalling. Trans signalling is associated with proinflammatory processes, including infiltration of granulocytes and macrophages during the late phase of an acute inflammation (described as the possible cause of tissue damage in the acute lung injury). Activation of gp130 via trans signalling is crucial for lymphocyte trafficking into inflamed areas by controlling chemokine expression 6 ; it promotes T-cell proliferation (for example, during colon cancer development) and is involved in regulating adhesion molecule expression on endothelial cells. 6 One additional player in trans signalling is soluble gp130 (sgp130), which is also constitutively present. 7 A significant anti-inflammatory response early in ARDS may provide a key mechanism for limiting the net inflammatory response in the lungs. 9 Therefore, preferential IL-6 trans pathway blockade may be superior to global (classic and trans) pathway blockade in the treatment of COVID-19 ARDS. The complexity of IL-6 signalling gives insight into why blockade of IL-6 (via, for example, SIL) or IL-6R (via, for example, TCZ) alone may not be sufficient to decrease IL-6-mediated signal transduction to a clinically relevant extent in COVID-19-related ARDS. Drug and molecular target nomenclature conforms to the IUPHAR/ BPS Guide to Pharmacology nomenclature classification. 10 For the purpose of the present analysis, with respect to IL-6 and sIL-6R concentrations, normal levels, levels in at-risk subjects on Day 1, and levels in ARDS subjects on Day 1 were extracted (median, 25th, 75th percentiles) and analysed as log-normal distributions. In total, 300 subjects were simulated from these lognormal distributions. The degree of variability reported in Park et al. exceed 100% for both IL-6 and sIL-6R in the at-risk and ARDS population, so betweenpatient variability is an important consideration. Table 1 Notably, the induction level of IL-6 and sIL-6R in ARDS relative to normal is 370-fold and 4.88-fold, respectively. Given a reported Kd value for sIL-6R to IL-6 of 5500 pM, binding is not favoured and the free moiety forms predominate over the complex IL-6:sIL-6R (CR). The induced IL-6:sIL-6R complex level in ARDS relative to normal is 1810-fold. While out-of-scope for this analysis, affinity for the IL-6: sIL-6R complex for gp130 is in the range of 10 pM, so the predicted increase in available IL-6:sIL-6R complex should be understood in that context. This is a placeholder, suggesting the location of Table 2 . The mean peak serum concentration of SIL following the first dose of SIL 11 mg/kg IV in patients with multicentric Castleman's disease was derived from the mean steady-state maximum concentration (Cmax) of 322 μg/mL divided by the accumulation ratio (1.7), or 195 μg/mL. 12 A dissociation equilibrium binding constant (Kd) for SIL has been reported as 15 pM. 13 The mean peak serum concentration of TCZ following the first dose of TCZ 8 mg/kg in patients with CRS during chimeric antigen receptor T-cell treatment is 99.5 μg/mL. 14 A Kd for TCZ has been reported as 1240 pM. 15 Biodistribution mechanisms and data for therapeutic monoclonal antibodies were taken from published literature. 16 Figure 2 ) and 1241 pM for TCZ:sIL-6R (Kd_TR in Figure 2 ). CR is the complex that (presumably) signals through the ubiquitously expressed gp130 receptor. In stoichiometric form: These reactions were implemented as a system of ordinary differential equations. Initial conditions of IL-6 (C) and sIL-6R (R) were given from the BALF concentration data in normal, pre-ARDS and ARDS subjects from the above Solving the resulting equilibrium equations may be possible, but these authors opted instead to simply simulate from the (dynamic) ordinary-differential equations out to steady-state. Off-rates were set to 0.1 s À1 for each reaction, so on-rates were derived kon = koff Kd-1. Although the off-rate is much more rapid than is typical for antibodies, the simulations were run out to steady-state so this assump- The binding models were used to generate simulated BALF concentra- Results are displayed in Figure 3 and provided in numerical form in Table 3 . sIL-6R complex reduction is predicted to be greater than monotherapy. This reflects sequestration of both components of the complex and the nonlinear binding equilibrium. In 1 study, 9 individual cytokines increased in patients before and after the onset of non-COVID- 19 ARDS, yet greater increases occurred in cognate receptors and/or antagonists, so that the molar ratios of agonists to antagonists declined dramatically at the onset of non-COVID-19 ARDS and remained low for at least 7 days. In that study, 9 The clinical results are consistent with the simulation findings. With TCZ intervention alone, IL-6 levels are unaffected, sIL-6R is normalized and the IL-6:sIL-6R complex largely unchanged. In contrast, with SIL intervention alone, sIL-6R levels are unaffected, IL-6 is greatly reduced and the IL-6:sIL-6R complex is greatly reduced. If the IL-6:sIL-6R complex signalling is responsible for clinical manifestations, that would suggest SIL is superior to TCZ, which appears to be bearing out in contemporary clinical trials. While both SIL and TCZ block IL-6:sIL-6R signalling, they do so through binding different components ( Figure 2 ) so the assumption that these treatments are interchangeable may not be valid. Further, these simulations suggest that the combination of SIL + TCZ would yield further reductions in IL-6: for IL-6:sIL-6R is higher than IL-6 for sIL-6R, suggesting that the limiting step is the binding of IL-6 to sIL-6R. Finally, a review of the literature revealed a range of binding constants reported for SIL:IL-6 and TCZ:sIL-6R ( Table 2 ). The selection of Kd for use in the model was the median reported value (Table 2, Figure 2 ). The impact of the true Kds being lower or higher is not accounted for in this work. T A B L E 3 Simulated IL-6, sIL-6R and IL-6:sIL-6R BALF Concentrations As is the case in all novel pandemics, this approach is limited by a lack of time and a lack of information. The novel nature of the disease limits the information we have on the virus and the trajectory of disease progression. The severity of disease limits the time we have to research the disease and attack drug development in the typical paradigm. For these reasons, we are constrained to make many assumptions, some of which are highlighted below. Antibody penetration into the lung has been studied for anti-RSV anti- An important caveat of these simulations is to understand that they are made: (i) based on the assumption that the maximal drug concentration instantaneously arrives in the BALF at a predefined ratio; and (ii) equilibrium binding occurs instantaneously and total target concentrations do not change over time. We would expect that unbound TCZ or SIL would constantly cycle into the BALF allowing for more sIL-6R or IL-6, respectively, to be bound. However, TCZ or SIL concentrations would also be falling relative to the maximal concentrations used here. Moreover, these simulations do not account for the synthesis and turnover rates of sIL-6R and IL-6. If IL-6 is formed and turned over more rapidly, that would tilt the results towards TCZ's favour. Far more complex, dynamic calculations would be required to understand the push-pull of these effects on binding outcomes. Additionally, variability in TCZ and SIL pharmacokinetics should be considered in more complex simulations. That variability would be expressed in wider prediction intervals (Figure 3 whiskers) for cytokine concentrations. (IL-6 7-45 pg/mL) were reported in early COVID-19 studies. 21, 22 In some studies, 1000-fold increases in IL-6 above normal have been reported. 18 It is unclear how targeting normal (<7 pg/mL) serum IL-6 levels for patients with such large variation in serum IL-6 concentration will be beneficial. It is unclear whether IL-6 represents a biomarker or a central pathogenetic element of severe COVID-19 that should be used as a parameter for therapeutic intervention. It is also unclear if the SIL or TCZ dose will need to be adjusted based on serum IL-6 concentration. It is suggested that initial dosing follow approved labelling, and that a dose-ranging study is planned in early clinical development of the combination for COVID-19 ARDS. Because this simulation does not address the time-dependent aspect of IL-6 pathway blockade, the results cannot be used to justify timing of treatment relative to the onset of clinical symptoms. However, clinical data describing the increase in circulating IL-6, coupled with the differences in magnitude of IL-6 increase in patients with ARDS and those that have not yet developed ARDS suggests early treatment with SIL, bolstered by treatment with TCZ, could be beneficial. Care should be taken to not over-interpret these simulations to suggest that SIL should be preferred over TCZ. To the contrary, these simulations suggest that the combined effect of these drugs on reducing IL6:sIL6R complex, which is responsible for signalling via the trans pathway is better than the monotherapy results. In the context of so much uncertainty around target concentrations, target dynamics and relative importance of each target's contributions, combination therapy should be considered. Finally, it should be noted that anti-IL-6 therapy, anti-IL-6R therapy and combination anti-IL-6:IL-6R therapy could have differing efficacies. The nuances of IL-6 signalling must be taken into account when discussing antibodies that target the IL-6 signalling pathway, and we must not treat IL-6 and IL-6R targets or blockers interchangeably. and executed the pharmacometric model. All authors contributed to writing and reviewing the manuscript. All authors give final approval of the version to be published. Data for model development to support the findings of this study were derived from public domain resources: Acute respiratory distress syndrome: new definition, current and future therapeutic options Global perspectives on COVID-19 Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis Dynamic Interleukin-6 Level Changes as a Prognostic Indicator in Patients With COVID-19 by the NIH/FDA Immunology and Cytokine Interest Groups and was purposed to discuss our rapidly changing understanding of COVID-19-related cytokine responses in different stages of infection, including the etiologies, downstream consequences and possible mitigation strategies. The recording is The Pro-And Anti-Inflammatory Properties of the Cytokine interleukin-6 IL-6 trans-signaling via the Soluble il-6 receptor: importance for the pro-inflammatory activities of IL-6 The IL-6/sIL-6R complex as a novel target for therapeutic approaches Cytokine balance in the lungs of patients with acute respiratory distress syndrome The Concise Guide to PHARMACOLOGY 2015/16 Covid 19: Informal consultation on the potential role of IL-6/IL-1 antagonists in the clinical management of COVID 19 infection Sylvant Highlights of Prescribing Information CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease Association of serum interleukin-6, interleukin-8, and Acute Physiology and Chronic Health Evaluation II score with clinical outcome in patients with acute respiratory distress syndrome Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Is a "Cytokine Storm" Relevant to COVID-19? Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation Supporting Information section at the end of this article. How to cite this article COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab The authors would like to acknowledge Synchrogenix for medical writing assistance. Funding for this work was made possible in part by a grant from the Bill and Melinda Gates Foundation. All authors are employees of Certara, Inc.